Search results for "Genetics"

showing 10 items of 12494 documents

Conserved TCR β chain usage in reactive arthritis; evidence for selection by a putative HLA-B27-associated autoantigen

2002

Previous work suggested that expanded CD8+ T-cell clones in the synovial fluid (SF) of HLA-B27+ patients with reactive arthritis (ReA) preferentially use the T-cell receptor variable region (TCRBV) 1, similar CDR3 sequences, and joining region (BJ) 2S3. To determine the range of conservation and disease-specificity of CDR3-sequences, we analyzed the TCRBV1-J2S3 repertoire from 33 healthy HLA-B27+ individuals, patients with various types of spondyloarthropathies (SpA), and with rheumatoid arthritis (RA) by CDR3-spectratyping. After collection and database submission of all available TCRB-CDR3 from HLA-B27-restricted or SpA-derived T cells, we systematically screened the entire human sequence…

musculoskeletal diseasesGeneticsHLA-B27T cellImmunologyT-cell receptorArthritisGeneral MedicineBiologymedicine.disease_causemedicine.diseaseBiochemistryConserved sequenceAutoimmunitymedicine.anatomical_structureAntigenGeneticsmedicineImmunology and Allergyskin and connective tissue diseasesCD8Tissue Antigens
researchProduct

H2-M polymorphism in mice susceptible to collagen-induced arthritis involves the peptide binding groove.

1996

The ability to develop type II collagen (CII)-induced arthritis (CIA) in mice is associated with the major histocompatibilityI-A gene and with as yet poorly defined regulatory molecules of the major histocompatibility complex (MHC) class II antigen processing and presentation pathway. H2-M molecules are thought to be involved in the loading of antigenic peptides into the MHC class II binding cleft. We sequencedH2-Ma, H2-Mb1, andH2-Mb2 genes from CIA-susceptible and-resistant mouse strains and identified four differentMa andMb2 alleles and three differentMb1 alleles defined by polymorphic residues within the predicted peptide binding groove. Most CIA-resistant mouse strains share commonMa, M…

musculoskeletal diseasesImmunologyGenes MHC Class IIMolecular Sequence DataGenes MHC Class IPeptide bindingMice Inbred StrainsMajor histocompatibility complexEpitopeMiceAntigenMHC class IGeneticsAnimalsAmino Acid SequencePhylogenyDNA PrimersMHC class IIPolymorphism GeneticbiologyBase SequenceSequence Homology Amino AcidAntigen processingH-2 AntigensHistocompatibility Antigens Class IIMolecular biologyArthritis ExperimentalHistocompatibilityHaplotypesbiology.proteinCollagenSequence AlignmentImmunogenetics
researchProduct

Interleukin 10 polymorphisms in ankylosing spondylitis.

2003

Genetic polymorphisms of the IL10 promoter region have been implicated in many autoimmune diseases, including seronegative spondyloarthropathies. We studied three SNPs (IL10-1087, -824, and -597) and two microsatellites (IL10R and IL10G) lying within the promoter region of IL10 for association with susceptibility to and clinical manifestations of ankylosing spondylitis (AS), a common form of spondyloarthritis. Four hundred and sixty-eight individuals from 182 Finnish families affected with AS were studied. No association between individual IL10 promoter region polymorphisms or marker haplotype was observed with susceptibility to AS, but weak association was noted between the IL10-597 and -8…

musculoskeletal diseasesImmunologychemical and pharmacologic phenomenaSingle-nucleotide polymorphismBiologyPolymorphism Single Nucleotideimmune system diseasesparasitic diseasesGeneticsmedicineSNPHumansSpondylitis AnkylosingAlleleSpondylitisGenetics (clinical)AllelesGenetic associationGeneticsAnkylosing spondylitisPolymorphism GeneticHaplotypehemic and immune systemsmedicine.diseaseInterleukin-10ImmunologyBASFIMicrosatellite Repeats
researchProduct

The campomelic syndrome: review, report of 17 cases, and follow-up on the currently 17-year-old boy first reported by Maroteaux et al in 1971.

1983

We report 17 cases of the campomelic syndrome (CS) and a follow-up of one of the original patients of Maroteaux et al who is now 17 years old. Our review is based on 97 patients, including our own. An infant with the CS presents at birth with spectacularly short and bowed femora and tibiae. The initial chest radiograph confirms the diagnosis by demonstrating extremely small bladeless scapulae and hypoplastic pedicles of many thoracic vertebrae. Ossification of the sternal segments, pubis, talus, and knee epiphyses is also retarded. Usually the hips are dislocated and talipes equinovarus deformities are present. There is a small chondrocranium and a disproportionately large neurocranium. The…

musculoskeletal diseasesMaleAdolescentH-Y AntigenRespiratory SystemBone and BonesmedicineHumansAbnormalities MultipleGenitaliaHydronephrosisGenetics (clinical)Respiratory Distress Syndrome NewbornRespiratory distressmedicine.diagnostic_testOssificationbusiness.industryInfant NewbornAnatomySyndromemusculoskeletal systemmedicine.diseaseRenal hypoplasiaHypotoniaCampomelic dysplasiamedicine.anatomical_structureCartilageThoracic vertebraeFemalemedicine.symptomChest radiographbusinessAmerican journal of medical genetics
researchProduct

Chondrodysplasia punctata, tibia-metacarpal (MT) type.

1990

We describe 7 patients with a new form of chondrodysplasia punctata. Its principal clinical manifestations are flat midface and nose, short limbs, and otherwise normal development. Consistent radiologic manifestations in the newborn infant are discrete calcific stippling, coronal clefts of vertebral bodies, short tibiae, and shortness of the 2nd and 3rd metacarpal bones. Radiologic findings in the older child include shortness of tibiae and the 3rd and 4th metacarpals.

musculoskeletal diseasesMaleChondrodysplasia PunctataAdolescentLimb Deformities CongenitalMetacarpal bonesShort staturemedicineHumansChondrodysplasia punctataAbnormalities MultipleTibiaChildGenetics (clinical)NoseShort tibiaTibiabusiness.industryInfant NewbornInfantAnatomymusculoskeletal systemmedicine.diseaseOsteochondrodysplasiamedicine.anatomical_structureShort limbsChild PreschoolFaceFemalemedicine.symptomMetacarpusbusinessAmerican journal of medical genetics
researchProduct

Evaluation of the osteoclastogenic process associated with RANK / RANK-L / OPG in odontogenic myxomas

2018

Background Odontogenic myxoma (OM) is a benign intraosseous neoplasm that exhibits local aggressiveness and high recurrence rates. Osteoclastogenesis is an important phenomenon in the tumor growth of maxillary neoplasms. RANK (Receptor Activator of Nuclear Factor κappa B) is the signaling receptor of RANK-L (Receptor activator of nuclear factor kappa-Β ligand) that activates the osteoclasts. OPG (osteoprotegerin) is a decoy receptor for RANK-L that inhibits pro-osteoclastogenesis. The RANK / RANKL / OPG system participates in the regulation of osteolytic activity under normal conditions, and its alteration has been associated with greater bone destruction, and also with tumor growth. Object…

musculoskeletal diseasesMaleOdontogenic myxomaRANK-LRANKOdontogenic myxoma03 medical and health sciences0302 clinical medicineOsteoprotegerinOsteoclastogenesis.MedicineNeoplasmHumansMIXOMAReceptorGeneral DentistryLanguageOSTEOGENESISDental follicleOral Medicine and PathologybiologyActivator (genetics)business.industryResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDental follicleLIGANDO RANKOtorhinolaryngologyRANKL030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASCancer researchbiology.proteinImmunohistochemistryOPGSurgerybusinessMyxomaMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

FGFR2mutation in 46,XY sex reversal with craniosynostosis

2015

Patients with 46,XY gonadal dysgenesis (GD) exhibit genital anomalies, which range from hypospadias to complete male-to-female sex reversal. However, a molecular diagnosis is made in only 30% of cases. Heterozygous mutations in the human FGFR2 gene cause various craniosynostosis syndromes including Crouzon and Pfeiffer, but testicular defects were not reported. Here, we describe a patient whose features we would suggest represent a new FGFR2-related syndrome, craniosynostosis with XY male-to-female sex reversal or CSR. The craniosynostosis patient was chromosomally XY, but presented as a phenotypic female due to complete GD. DNA sequencing identified the FGFR2c heterozygous missense mutatio…

musculoskeletal diseasesMalemedicine.medical_specialtyGonadAdolescentDNA Mutational AnalysisMutation MissenseGonadal dysgenesisBiologymedicine.disease_causeCraniosynostosisXY gonadal dysgenesisCraniosynostosesMiceInternal medicineGeneticsmedicineAnimalsHumansMissense mutationGene Knock-In TechniquesReceptor Fibroblast Growth Factor Type 2Molecular BiologyGenetics (clinical)Gonadal Dysgenesis 46XYGeneticsMutationArticlesSyndromeGeneral MedicineSex reversalmedicine.diseaseMice Mutant StrainsDisease Models AnimalEndocrinologymedicine.anatomical_structurePfeiffer syndromeFemaleHuman Molecular Genetics
researchProduct

Transient regional osteoporosis.

2014

Transient regional osteoporosis (TRO) is a disease that predisposes to fragility fracture in weight bearing joints of mid-life women and men. Pregnant women may also suffer the process, usually at the hip. The prevalence of TRO is lower than the systemic form, associated with postmenopause and advanced age, but may be falsely diminished by under-diagnosis. The disease may be uni- or bilateral, and may migrate to distinct joints. One main feature of TRO is spontaneous recovery. Pain and progressive limitation in the functionality of the affected joint(s) are key symptoms. In the case of the form associated with pregnancy, difficulties in diagnosis derive from the relatively young age at pres…

musculoskeletal diseasesMalemedicine.medical_specialtyPediatricsOsteoporosisDiseasemedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyWeight-bearingPregnancymedicineHumansPregnancyHip fracturebusiness.industryObstetrics and GynecologyJoint effusionmedicine.diseaseSurgeryOrthopedic surgeryGestationOsteoporosisFemalemedicine.symptomJoint DiseasesbusinessMaturitas
researchProduct

The role of biosilica in the osteoprotegerin/RANKL ratio in human osteoblast-like cells

2010

Abstract Earlier studies have demonstrated that biosilica, synthesized by the enzyme silicatein, induces hydroxyapatite formation in osteoblast-like SaOS-2 cells. Here we study the effect of biosilica on the expressions of osteoprotegerin [OPG] and the receptor activator for NF-κB ligand [RANKL] in the SaOS-2 cell model. We show that during growth of SaOS-2 cells on biosiliceous matrices hydroxyapatite formation is induced, while syntheses of cartilaginous proteoglycans and sulfated glycosaminoglycans are down-regulated. Furthermore, quantitative real-time RT-PCR analysis revealed a strong time-depended increase in expression of OPG in biosilica exposed SaOS-2 cells while the steady-state e…

musculoskeletal diseasesMaterials scienceCell Culture TechniquesBiophysicsBiocompatible MaterialsBioengineeringCell LineBiomaterialsGlycosaminoglycanSulfationOsteoprotegerinMaterials TestingmedicineAnimalsHumansReceptorchemistry.chemical_classificationOsteoblastsbiologyActivator (genetics)RANK LigandOsteoprotegerinOsteoblastSilicon DioxideCathepsinsExtracellular MatrixCell biologyEnzymemedicine.anatomical_structurechemistryBiochemistryMechanics of MaterialsRANKLCeramics and Compositesbiology.proteinBiomaterials
researchProduct

AB0465 Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity

2013

Background Rheumatoid arthritis (RA) is conventionally defined as moderate when the disease activity score assessed in 28 joints (DAS28) is ≥3.2, and high disease with DAS28 >5.1 Objectives Aim of this analysis was to evaluate the rate of remission and LDA (low disease activity), in RA patients starting etanercept therapy with moderate disease activity in the real world settings Methods The clinical records were retrospectively analysed from the Italian nationwide registry, called GISEA (Gruppo Italiano Studio Early Arthritis). RA patients with moderate (Mod-RA) and high (H-RA) disease activity (DAS28 >3.2) with incomplete response to conventional DMARDs and beginning a treatment with etane…

musculoskeletal diseasesModerate to severemedicine.medical_specialtybusiness.industryImmunologySevere diseaseDiseasemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyEtanerceptSurgeryRheumatologyStandard careRheumatoid arthritisInternal medicineImmunology and AllergyMedicineEtanercept therapybusinessEarly arthritismedicine.drugAnnals of the Rheumatic Diseases
researchProduct